FDA Approves Alzheimer's Drug Lecanemab Amid Safety Concerns

Overview

Journal Nature

Specialty Science

Date 2023 Jan 10

PMID 36627422

Authors

Sara Reardon

Affiliations

Soon will be listed here.

Citing Articles

C-Labeling of a Flavanone Extracted from a South American Native Species for Evaluation of Its Interaction with GSK-3β.

Zeni M, Santi M, Arredondo F, Reyes L, Bentura M, Carvalho D Molecules. 2025; 30(4).

PMID: 40005183 PMC: 11857971. DOI: 10.3390/molecules30040874.

Discovery of Effective Inhibitors Against Phosphodiesterase 9, a Potential Therapeutic Target of Alzheimer's Disease with Antioxidant Capacities.

Zhou Q, Wu X, Luo W, Huang Q, Feng L, Wu Y Antioxidants (Basel). 2025; 14(2).

PMID: 40002310 PMC: 11852235. DOI: 10.3390/antiox14020123.

A systematic exposure-wide framework leveraging machine learning to identify multidomain exposure factors and their joint influence on cognitive function: Evidence from a neurological cohort.

Wu J, Yin B, Wen R, Pei H, Zhu S, Zhao J Alzheimers Dement. 2025; 21(2):e14624.

PMID: 39998468 PMC: 11853734. DOI: 10.1002/alz.14624.

Investigation of Novel Aronia Bioactive Fraction-Alginic Acid Nanocomplex on the Enhanced Modulation of Neuroinflammation and Inhibition of Aβ Aggregation.

Jang B, Shin S, Park H, Kumar V, Park Y, Kim J Pharmaceutics. 2025; 17(1).

PMID: 39861665 PMC: 11769017. DOI: 10.3390/pharmaceutics17010013.

Effect of Low-Frequency, Low-Energy Pulsed Electromagnetic Fields in Neuronal and Microglial Cells Injured with Amyloid-Beta.

Merighi S, Nigro M, Travagli A, Fernandez M, Vincenzi F, Varani K Int J Mol Sci. 2024; 25(23).

PMID: 39684558 PMC: 11641689. DOI: 10.3390/ijms252312847.

References

van Dyck C, Swanson C, Aisen P, Bateman R, Chen C, Gee M . Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2022; 388(1):9-21. DOI: 10.1056/NEJMoa2212948. View